HRMY - Mizuho says market fears for Harmony's Wakix drug are overblown
2023-10-04 12:32:07 ET
More on Harmony Biosciences
- Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep
- Harmony Biosciences Holdings, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Harmony Biosciences Holdings, Inc. (HRMY) Q2 2023 Earnings Call Transcript
- Harmony Biosciences subsidiary extends expiration of offer to acquire Zynerba
- Harmony Bio falls as Goldman Sachs cuts to Sell on revenue risks
For further details see:
Mizuho says market fears for Harmony's Wakix drug are "overblown"